BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33790551)

  • 21. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study.
    Jiang L; Kendzerska T; Aaron SD; Stukel TA; Stanbrook MB; Tan W; Pequeno P; Gershon AS
    COPD; 2022; 19(1):315-323. PubMed ID: 35946353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of different inhalation therapies on less symptomatic chronic obstructive pulmonary disease patients in a Chinese population: a real-world study.
    Song Q; Lin L; Zhou A; Cheng W; Liu C; Peng Y; Zhou Z; Zeng Y; Deng D; Liu D; Yu Z; Chen Y; Cai S; Chen P
    Ann Med; 2023 Dec; 55(1):1317-1324. PubMed ID: 36988161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study.
    Suissa S; Dell'Aniello S; Ernst P
    COPD; 2021 Feb; 18(1):1-8. PubMed ID: 33569990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline.
    Nici L; Mammen MJ; Charbek E; Alexander PE; Au DH; Boyd CM; Criner GJ; Donaldson GC; Dreher M; Fan VS; Gershon AS; Han MK; Krishnan JA; Martinez FJ; Meek PM; Morgan M; Polkey MI; Puhan MA; Sadatsafavi M; Sin DD; Washko GR; Wedzicha JA; Aaron SD
    Am J Respir Crit Care Med; 2020 May; 201(9):e56-e69. PubMed ID: 32283960
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England.
    Sansbury LB; Lipson DA; Bains C; Anley GA; Rothnie KJ; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():415-426. PubMed ID: 35264848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
    Bloom CI; Elkin SL; Quint JK
    Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S; Dell'Aniello S; Ernst P
    Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
    Wilkie M; Finch S; Schembri S
    COPD; 2015; 12(5):582-90. PubMed ID: 25774769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
    Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
    NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple inhaled therapy in COPD patients: determinants of prescription in primary care.
    Vetrano DL; Zucchelli A; Bianchini E; Cricelli C; Piraino A; Zibellini M; Ricci A; Onder G; Lapi F
    Respir Med; 2019; 154():12-17. PubMed ID: 31202120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status.
    Reilev M; Kristensen KB; Søndergaard J; Henriksen DP; Thompson W; Pottegård A
    Eur J Clin Pharmacol; 2019 Jul; 75(7):1025-1032. PubMed ID: 30903196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of use of long-acting bronchodilators in patients with COPD: A nationwide follow-up study of new users in New Zealand.
    Parkin L; Barson D; Zeng J; Horsburgh S; Sharples K; Dummer J
    Respirology; 2018 Jun; 23(6):583-592. PubMed ID: 29265705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
    Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
    Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
    Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Esposito I; Pistelli R; Martini N
    Pulm Pharmacol Ther; 2020 Apr; 61():101904. PubMed ID: 32092473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
    Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
    COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
    Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
    J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.